Oct. 26 at 10:53 PM
$INVO This will be positive RK.
“AstraZeneca is transitioning from using American Depositary Receipts (ADRs) to directly listing its ordinary shares on the New York Stock Exchange (NYSE), a move designed to harmonize its stock listings across the London Stock Exchange, Nasdaq Stockholm, and NYSE. This change will allow shareholders to trade AstraZeneca shares directly on all three exchanges, rather than through the ADR system on Nasdaq, making it easier and more direct for U.S. investors to buy shares. AstraZeneca will maintain its primary listing and headquarters in the UK.
Current change: The company is moving to a direct listing of its ordinary shares on the NYSE, replacing the ADRs.
Purpose: This "harmonization" aims to simplify the shareholder experience and make it easier for global investors, especially those in the US, to trade the company's stock directly.